Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC)

Update to information on psychiatric disorders for chloroquine and hydroxychloroquine EMA’s safety committee (PRAC) has recommended updating the product information for all chloroquine or hydroxychloroquine-containing medicines following a review of all available data that confirmed a link between the use of these medicines and the risk of psychiatric disorders and suicidal behaviour.